The clinical progress is positive but expected; cash runway remains tight despite the recent $10M offering. Watch for enrollment completion and top-line data in early 2027, which are the primary catalysts. The increased loss rate keeps dilution risk alive.
ANVS drugs
ANVS drug pipeline →Price Chart
Executive Summary
Annovis Bio reported Q1 2026 results showing increased net loss per share ($0.63 vs $0.32) and cash burn, but highlighted strong enrollment progress in its pivotal Phase 3 Alzheimer's trial (85% enrolled) and Parkinson's open-label extension study (40% enrolled), along with a positive DSMB recommendation. The clinical milestones support the NDA timeline but financial deterioration is a concern.
Key Financial Metrics
Key Facts
- Phase 3 AD trial enrollment at 85%; full enrollment on track for summer 2026
- PD OLE study enrollment at 40%; full enrollment expected Q4 2026
- Positive DSMB recommendation for buntanetap safety at 6 months
- Net loss per share widened to $0.63 from $0.32 in Q1 2025
- Cash and equivalents $14.2M as of March 31, 2026, plus $10M April direct offering
- NDA submission for symptomatic AD treatment expected early 2027
Financial Impact
Net loss increased to $17.6M from $5.5M year-over-year; cash burn accelerated due to Phase 3 trial costs
Risk Factors
- Clinical trial failure or data miss could devastate stock
- Cash burn may require additional dilutive financing before data readout
- Regulatory path for NDA uncertain until Phase 3 results
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-062451 |
| Document: tm2614822d1_8k.htm | 0001104659-26-062451 |
| Document: 0001104659-26-062451-index-headers.html | 0001104659-26-062451 |
| Document: 0001104659-26-062451-index.html | 0001104659-26-062451 |
| Document: 0001104659-26-062451.txt | 0001104659-26-062451 |
| 8-K Data (Synthetic) | 0001104659-26-062451 |
Track record
19 reports on ANVS
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +19.53% at T+20 after the May 20, 2026 report. 4 of 10 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.9261 Now $0.7500 −19.02% settles Feb 11
- Nov 5, 202611d ago 8-K Bearish 7/10 Entry $0.8449 Now $0.7500 +11.23% settles Feb 4
- Nov 5, 202611d ago 424B5 Bearish 7/10 Entry $0.8449 Now $0.7500 +11.23% settles Feb 4
- Nov 5, 202611d ago Press Release Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Nov 4, 202612d ago 424B5 Bearish 6/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Nov 4, 202612d ago Press Release Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Nov 4, 202612d ago 8-K Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Oct 30, 202617d ago 8-K Bearish 7/10 Entry $1.08 Now $0.7500 +30.56% settles Jan 29
- Oct 19, 202628d ago 8-K Neutral 1/10 Entry $0.9783 Now $0.7500 −23.34% settles Jan 15
- Oct 15, 20264w ago SC 13G/A Neutral 3/10 Entry $1.05 Now $0.7500 −28.57% settles Jan 12
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers